<DOC>
	<DOCNO>NCT02230514</DOCNO>
	<brief_summary>The present study evaluate effect XCEL-MT-OSTEO-ALPHA non-union fracture ( pseudoarthrosis ) long bone comparison standard treatment autologous iliac crest . XCEL-MT-OSTEO-ALPHA tissue engineering product compose `` ex-vivo '' expand autologous mesenchymal stromal cell fix allogenic bone tissue , produce Xcelia ( Blood Tissue Bank Catalonia ) . The work hypothesis proposes tissue engineering valid useful technique achieve bone regeneration consolidation non-union fracture .</brief_summary>
	<brief_title>Mesenchymal Stromal Cells Treatment Non-union Fractures Long Bones</brief_title>
	<detailed_description>A phase IIa , single center , prospective , randomize , parallel , two-arms , single-dose , open-label blind assessor pilot clinical trial ass ex vivo expand adult autologous mesenchymal stromal cell fix allogeneic bone tissue ( XCEL-MT-OSTEO-ALPHA ) non hypertrophic pseudoarthrosis long bone .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Fractures , Ununited</mesh_term>
	<criteria>18 85 year age ( male female ) Atrophic hypotrophic metaphysealdiaphyseal pseudarthrosis long bone , confirm radiographically . Signed Informed Consent Form The patient able understand nature study Suspicious pseudarthrosis focus infection diagnose clinical inspection blood analysis . Positive serology HIV ( AntiHIV I/IIAc ) , Hepatitis B ( HBsAg , HBcAc ) , Hepatitis C ( AntiHCVAc ) Syphilis LÃºes ( TPAc ) . Significant abnormal laboratory test contraindicate patient 's participation study . Pregnant woman without proper anticonceptive measure accord investigator , breath feeding Smoker 15 cigarette day Congenital disorder bone ( hypophosphatemia ) , bone metabolic disorder associate primary secondary hypoparathyroidism . Badly manage diabetes mellitus . Patients diagnose peripheral arterial disorder Previous therapeutic radiation ( 5 previous year ) affect bone . Neoplasia within previous 5 year , without remission The patient legally dependent Participation another clinical trial treat investigational medicinal product previous 30 day Other pathologic condition circumstance difficult participation study accord medical criterion The patient accept followedup period could exceed clinical trial length</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Nonunion fracture</keyword>
	<keyword>Long bone</keyword>
	<keyword>Pseudoarthrosis</keyword>
	<keyword>Cell therapy</keyword>
	<keyword>Tissue engineering</keyword>
	<keyword>Mesenchymal stromal cell</keyword>
</DOC>